These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15612454)

  • 1. Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study.
    Cheung AT; Chan MS; Ramanujam S; Rangaswami A; Curl K; Franklin P; Wun T
    J Investig Med; 2004 Sep; 52(6):402-6. PubMed ID: 15612454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial.
    Orringer EP; Casella JF; Ataga KI; Koshy M; Adams-Graves P; Luchtman-Jones L; Wun T; Watanabe M; Shafer F; Kutlar A; Abboud M; Steinberg M; Adler B; Swerdlow P; Terregino C; Saccente S; Files B; Ballas S; Brown R; Wojtowicz-Praga S; Grindel JM
    JAMA; 2001 Nov; 286(17):2099-106. PubMed ID: 11694150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
    Casella JF; Barton BA; Kanter J; Black LV; Majumdar S; Inati A; Wali Y; Drachtman RA; Abboud MR; Kilinc Y; Fuh BR; Al-Khabori MK; Takemoto CM; Salman E; Sarnaik SA; Shah N; Morris CR; Keates-Baleeiro J; Raj A; Alvarez OA; Hsu LL; Thompson AA; Sisler IY; Pace BS; Noronha SA; Lasky JL; de Julian EC; Godder K; Thornburg CD; Kamberos NL; Nuss R; Marsh AM; Owen WC; Schaefer A; Tebbi CK; Chantrain CF; Cohen DE; Karakas Z; Piccone CM; George A; Fixler JM; Singleton TC; Moulton T; Quinn CT; de Castro Lobo CL; Almomen AM; Goyal-Khemka M; Maes P; Emanuele M; Gorney RT; Padgett CS; Parsley E; Kronsberg SS; Kato GJ; Gladwin MT
    JAMA; 2021 Apr; 325(15):1513-1523. PubMed ID: 33877274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purified poloxamer 188 for sickle cell vaso-occlusive crisis.
    Gibbs WJ; Hagemann TM
    Ann Pharmacother; 2004 Feb; 38(2):320-4. PubMed ID: 14742772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
    Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
    Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial.
    Qari MH; Aljaouni SK; Alardawi MS; Fatani H; Alsayes FM; Zografos P; Alsaigh M; Alalfi A; Alamin M; Gadi A; Mousa SA
    Thromb Haemost; 2007 Aug; 98(2):392-6. PubMed ID: 17721622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal fentanyl for initial treatment of vaso-occlusive crisis in sickle cell disease.
    Fein DM; Avner JR; Scharbach K; Manwani D; Khine H
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27862905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjunctival microvascular hemodynamics following vaso-occlusive crisis in sickle cell disease.
    Kord Valeshabad A; Wanek J; Gaynes B; Saraf SL; Molokie R; Shahidi M
    Clin Hemorheol Microcirc; 2015 Sep; 62(4):359-67. PubMed ID: 26444608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
    Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW;
    Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.
    Manwani D; Frenette PS
    Hematology Am Soc Hematol Educ Program; 2013; 2013():362-9. PubMed ID: 24319205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease.
    Weiner DL; Hibberd PL; Betit P; Cooper AB; Botelho CA; Brugnara C
    JAMA; 2003 Mar; 289(9):1136-42. PubMed ID: 12622584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition.
    Sarray S; Saleh LR; Lisa Saldanha F; Al-Habboubi HH; Mahdi N; Almawi WY
    Cytokine; 2015 Mar; 72(1):43-7. PubMed ID: 25569375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
    Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
    N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New advances in the treatment of sickle cell disease: focus on perioperative significance.
    Dix HM
    AANA J; 2001 Aug; 69(4):281-6. PubMed ID: 11759366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study.
    Cheung AT; Chen PC; Larkin EC; Duong PL; Ramanujam S; Tablin F; Wun T
    Blood; 2002 Jun; 99(11):3999-4005. PubMed ID: 12010800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
    Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI
    Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.
    Telen MJ; Wun T; McCavit TL; De Castro LM; Krishnamurti L; Lanzkron S; Hsu LL; Smith WR; Rhee S; Magnani JL; Thackray H
    Blood; 2015 Apr; 125(17):2656-64. PubMed ID: 25733584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of platelet activation in sickle cell anaemia.
    Ibanga IA
    Niger J Med; 2006; 15(2):148-50. PubMed ID: 16805172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of microcirculation abnormalities in sickle cell patients upon buflomedil treatment.
    Bachir D; Maurel A; Beuzard Y; Razavian M; Kraiem A; Portos JL; Galacteros F
    Microvasc Res; 1993 Nov; 46(3):359-73. PubMed ID: 8121319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study on the efficacy of ketorolac plus tramadol infusion combined with erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle cell pain.
    de Franceschi L; Finco G; Vassanelli A; Zaia B; Ischia S; Corrocher R
    Haematologica; 2004 Nov; 89(11):1389-91. PubMed ID: 15531461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.